Dr. Manabe began her career working on the basic science aspects of tuberculosis (TB) immunopathogenesis in comparative animal models of infection, particularly latency, reactivation, and immune reconstitution inflammatory syndrome (IRIS) in the rabbit model within the Johns Hopkins Center for Tuberculosis Research. In 2007, she was seconded to the Infectious Diseases Institute (IDI) at Makerere College of Health Sciences as the Associate Medical Laboratory Director of the College of American Pathologists certified Makerere University-Johns Hopkins University Clinical Core Lab to study antiretroviral associated TB and IRIS. She then became the Head of Research at the IDI in 2008 until 2012 where she built research capacity and infrastructure for training Ugandan investigators.
Dr. Manabe has been doing operational and translational research in tuberculosis and HIV co-infection as well as evaluating TB and other infectious disease diagnostics. She is particularly interested in rapid, point-of-care infectious disease diagnostics suitable for the resource-limited settings particularly in sub-Saharan Africa (SSA). Her research has focused on accuracy testing of various rapid, point-of-care diagnostics for HIV and related infectious diseases of clinical importance in SSA. She is also interested in studying the impact of various diagnostic interventions on disease detection and patient outcomes.
Dr. Bollinger is the Raj and Kamla Gupta Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine, and he holds joint appointments in International Health at the Johns Hopkins (JH) Bloomberg School of Public Health, and in Community Public Health at the JH School of Nursing. He is Founding Director of the Center for Clinical Global Health Education (CCGHE), Director of the JHU Fogarty India Program, and Associate Director for Medicine of the JH Center for Global Health. He is board certified by the American Board of Internal Medicine in internal medicine and infectious diseases. Dr. Bollinger has more than 40 years of experience in international public health, clinical research, and education with such global health priorities as HIV/AIDS, malaria, tuberculosis, leprosy, dengue, antibiotic resistant infections and other emerging diseases. His research interests include identifying biological and behavioral risk factors for HIV transmission; characterizing the clinical progression and treatment of HIV and related infections; development/evaluation of novel point-of-care diagnostics and implementation of research projects to optimize healthcare capacity and delivery in resource-limited settings. Working with partners in more than 20 countries, Dr. Bollinger and CCGHE faculty pioneered the development and use of distance learning and the award-winning emocha mobile health platform.
Dr. Bollinger established health research and education programs in countries throughout Africa, South and Central America, Southeast Asia, and the Middle East. In 1991, he initiated an NIH-funded Indo-US HIV research program in Pune, India, involving the National AIDS Research Institute/ICMR and the BJ Government Medical College. He has served as Principal Investigator for many NIH-supported studies and clinical trials in Pune, India, including the SWEN study, which led to changes in World Health Organization (WHO) guidelines for treatment of infants born to HIV positive mothers to prevent mother-to-child transmission. He has participated in public health training programs and served on expert committees in more than 15 countries. He served as a member of the US Presidential Advisory Council for HIV/AIDS (PACHA), the PACHA International Sub-committee, the Institute of Medicine Forum on Public-Private Partnerships for Global Health and Safety, and is a current member of the NIH Fogarty International Center Advisory Board. He is an author of more than 200 peer-reviewed research publications and 15 book chapters, including the first and largest studies of risk factors for HIV transmission in India, the cloning and sequencing of the first HIV viruses from India, the only studies characterizing the primary immune response to HIV in India, and the demonstration of increased risk of HIV acquisition with recent HSV infection and lack of circumcision.
Dr. Bollinger received an undergraduate degree from Haverford College, a Doctor of Medicine from Dartmouth Medical School, and a Master of Public Health from JH Bloomberg School of Public Health. He completed his internal medicine training at the University of Maryland Medical Systems, followed by a post-doctoral fellowship in infectious diseases at JHU School of Medicine.
Dr. Chang is Associate Professor of Medicine, Epidemiology, and International Health at Johns Hopkins University. He is a physician trained in internal medicine, infectious diseases, and epidemiology with an interest in interdisciplinary, innovative, and pragmatic approaches to impacting the HIV pandemic. Dr. Chang has experience in HIV treatment and prevention, implementation science, cohort, community-based trials, and mixed methods research. He is currently a Co-PI of the Rakai Health Sciences Program (RHSP) in Uganda and is an active infectious diseases and HIV clinician. Dr. Chang is also involved with HIV implementation science research and capacity building as a former Director of the Johns Hopkins CFAR Implementation Science Working Group and current Director of the Inter-Centers for AIDS Research Sub-Saharan African Working Group (CFAR-SSA). Dr. Chang is also PI of a Fogarty training grant focused on capacity building to understand and end the HIV epidemic in Uganda. A related focus of Dr. Chang’s research is using mHealth (mobile technologies for health) strategies for improving global public health and clinical care. He is the Associate Director for the University-wide Johns Hopkins Global mHealth Initiative.
Dr. Clarke is a Professor of Pathology with the Johns Hopkins University School of Medicine. He received his Ph.D. in Analytical Chemistry from the University of Nebraska in Lincoln in 2000, followed by a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine, ending in 2002. In addition, he received an MBA focused on medical services management from the Carey School of Business at Johns Hopkins in 2007. Following his post-doctoral fellowship, he remained at Johns Hopkins, where he is a Professor in the Department of Pathology, as well as the director of both Point-of-Care Testing and Clinical Toxicology for the hospital. His research interests include clinical mass spectrometry, method development and evaluation for therapeutic drug monitoring, clinical toxicology, point-of-care testing, and development/validation of biomarkers for use in drug management. Dr. Clarke has published as author or co-author over 130 peer-reviewed manuscripts or book chapters, is the Co-Editor of the textbook Contemporary Practice in Clinical Chemistry, and is the Co-Editor-in-Chief of the journal Practical Laboratory Medicine.
Dr. Dowdy is general internist and infectious disease epidemiologist with interdisciplinary expertise in epidemiology, health economics, and mathematical modeling. My content area of greatest familiarity is mathematical and simulation modeling of interventions to control tuberculosis (TB) and HIV. In the field, I have collected empirical data to inform such models in over 10 countries across 4 continents. I have used such models to evaluate the epidemiological and economic impact of improved TB and HIV diagnostic and therapeutic strategies, both locally and globally. I serve on the steering committee of the Gates Foundation-funded TB Modeling and Analysis Consortium. I am also an active member of the Johns Hopkins Center for TB Research, Center for AIDS Research, and the Uganda Tuberculosis Implementation Research Consortium (U-TIRC).
Dr. Gaydos is a Professor in the Department of Medicine, Infectious Disease Division, Johns Hopkins University School of Medicine, Past President of the International Union Against Sexually Transmitted Infections (IUSTI), and member of the Center for Global Health. She received her M.S. in medical microbiology from West Virginia University. Her MPH and DrPH in immunology and infectious diseases were from Johns Hopkins University School of Public Health. She is the C0-Director of the University International STI, and Respiratory Diseases, Research Laboratory. She has over 45 years of experience in microbiology laboratory diagnostics in community acquired pneumonia and emerging/respiratory microbiology. She has authored 30 book chapters, >530 research articles, and >700 abstracts/oral presentations. Dr. Gaydos has conducted FDA clinical trials for new diagnostics for STIs, as well as for respiratory microorganisms. The CAP/CLIA-compliant laboratory is a CORE Diagnostic/Reference Laboratory for international studies of STIs, respiratory diseases, and trachoma. She has published regarding research for developing DNA amplification assays, and for epidemiological studies for STIs in schools, the military, and international populations, as well as studies of cost-effectiveness analyses. Dr. Gaydos was a Co-investigator for the Diagnostics Program for the NIH Mid-Atlantic Research Center of Excellence for 10 years for Emerging and Biothreat Diseases and participated in many community acquired pneumonia studies. She is the Co-P.I. of a NIH funded Center for the development of point of care POC diagnostics for STDs, as well as a co-investigator for the NIH Center of Excellence in Influenza Research and Surveillance.
Dr. Gupta is Deputy Director of the Johns Hopkins (JH) Center for Clinical Global Health Education (CCGHE), and Professor of Infectious Diseases at the JH School of Medicine, with a joint appointment in International Health at the JH Bloomberg School of Public Health. Board certified by the American Board of Internal Medicine in infectious diseases, Dr. Gupta specializes in international public health, clinical research, and education in infectious diseases, HIV/AIDS, tuberculosis (TB), and antimicrobial resistant infections. Since 2003, her work has been focused primarily on India, where she leads several Indo-JHU research collaborations. She serves in leadership positions as the US chair for the Indo-US Vaccine Action Program sponsored RePORT India TB research consortium and on the global RePORT International Executive Committee, a multilateral global consortia for TB research. She is Co-principal Investigator of the NIH-funded Baltimore-Washington-India HIV and Infectious Diseases Clinical Trials Unit (BWI-CTU), and she is an active clinical investigator in multi-country trials conducted by the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT), and has served as protocol chair for high impact findings published in The New England Journal of Medicine and The Lancet. She is Co-chair of the NIH and AmFAR funded IeDea HIV/TB Working Group and Scientific Committee co-Chair for IMPAACT TB. Dr. Gupta was appointed by the US Health and Human Services Secretary for a 4-year term to the NIAID Council, the chief advisory committee for National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health, and she is a member of the Governing Board of the Indo-U.S. Science & Technology Forum.
Dr. Gupta is an author of more than 180 peer-reviewed research publications and 7 book chapters. She has mentored more than 35 junior scientists in India and the US to run research studies and submit their own scientific findings to peer-reviewed publications. She received an undergraduate degree from MIT, a Doctor of Medicine from Harvard Medical School, and a Master of Health Sciences in clinical investigation from Johns Hopkins Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by a post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention (CDC, Foodborne and Diarrheal Diseases) and at the JHU School of Medicine (Infectious Diseases).
Dr. Matthew Hamill is a UK-trained physician with specialist accreditation in STI/HIV (genitourinary medicine). He has worked in STI/HIV clinics in the UK NHS service for many years, conducted clinical and research work in The Gambia, South Africa, Uganda and the United States. His current research efforts focus on point-of-care diagnostics for HIV/STD; LGV infection; syphilis epidemiology in Baltimore, and elucidating the microbiological causes of urethritis in Kampala, Uganda. He graduated from medical school in 1998 (MBChB, Bristol), trained in internal medicine (MRCP, UK) in London and STI/HIV also in London, UK. He underwent training in Tropical Medicine DTM&H (London School of Hygiene and Tropical Medicine) and further academic training PhD (Cambridge) and MPH (Harvard) with a focus on global health. His current primary research focus is point-of -care testing for STD/HIV and diagnostic certainty in resource-limited settings. He is Assistant Professor in the Division of Infectious Diseases at the Johns Hopkins School of Medicine and Clinical Chief for STD at Baltimore City Health Department.
Dr. Kendall is an Assistant Professor of Medicine in the Division of Infectious Diseases and the Center for TB Research. Her work, which combines epidemiological field studies and mechanistic modeling, seeks to provide guidance for the control of global TB epidemics. Areas of interest include dynamics and prevention of disease transmission, dynamics and prevention of drug resistance, and optimization of diagnostic strategies for case detection, treatment selection, and clinical risk stratification. https://scholar.google.com/citations?user=K26bSHMAAAAJ&hl=en
The Larman Laboratory develops and deploys cutting edge molecular assays to characterize human immune responses. Three technologies are being employed to identify biomarkers for COVID-19 patient stratification. First, we are measuring host immune response genes directly from nasal swabs. Second, we are profiling serum anti-viral antibody responses using a comprehensive binding assay. Third, adaptive immune receptor repertoires will be sequenced from peripheral blood mononuclear cells. Each approach provides a unique opportunity to identify immune response signatures with prognostic utility. https://labs.pathology.jhu.edu/larman/
Dr. Marr is a Professor of Medicine for Oncology, Business Director of the Transplant and Oncology Infectious Disease Program and Vice Chair of Medicine for Innovation in Healthcare Implementation.
Dr. Marr’s research focuses on clinical and translational investigations relating to fungal infections, with specialized expertise on diagnostics, host immunity, and prevention. She leads a translational research laboratory that focuses on development of diagnostic devices for fungal infections and on furthering our understanding of immunologic risks. She also leads the Transplant and Oncology Infectious Diseases program at JHU, a clinical research center that performs phase I – IV clinical trials, both industry and NIH – sponsored. Dr. Marr’s primary interests are in advancing approaches for preventing infections through translational and clinical study of the host-pathogen interaction during vulnerable states, clinical trial design, and promoting academic health innovation. She serves as Vice Chair for Innovation in the Department of Medicine and work to help product and business development across multiple arenas.
Dr. Marr’s laboratory has developed several diagnostics for fungal infections and has licensed technology to a JHU spinoff company located in a physically-adjacent accelerator, MycoMed Technologies. She has led both technical development in the laboratory as well as multicenter translational studies to enable performance evaluations. Since 2016, she has served as CEO of MycoMed, with a decrease in academic effort (to 75%), enabling protection of time to manage the company and oversee a team that is leading development of three diagnostics that were originally invented in my laboratory. The JHU – MycoMed collaboration has yielded 5 issued patents for diagnostics for aspergillosis and histoplasmosis, with the first FDA 510k application projected in 2Q2020. Diagnostics in development currently include: (1) MycoMEIA – a urine based ELISA for screening and aide to diagnose aspergillosis; and (2) MycoFLOW – a urine based lateral flow device for aspergillosis and HistoSPOT – interferon gamma release assay for latent and active histoplasmosis.
Dr. Robinson’s interest is in developing strategies for clinicians in low- and middle-income countries (LMICs) to reduce diagnostic uncertainty for acute febrile illness and judiciously choose antibiotics for patients with suspected bacterial infections. During more than a year of providing clinical care in public hospitals in Uganda and Rwanda, he encountered the daily challenge of diagnostic uncertainty for patients with acute febrile illness. During my infectious diseases and Fogarty Global Health fellowships, he worked at a public hospital in India to characterize the etiology of acute febrile illness and burden of antimicrobial resistance. As an Antibacterial Resistance Leadership Group fellow, he studied the relationship between diagnostic uncertainty for acute febrile illness and antibiotic use in India. He is currently leading an evaluation of a multiplex rapid diagnostic test for tropical causes of acute febrile illness and contributing to the development of multiple other novel diagnostics. https://main.ccghe.net/content/matt-robinson-md
Dr. Rothman, is the Executive Vice Chair and Vice Chair for Research for the Department of Emergency Medicine at Johns Hopkins University. He is also a Professor of Emergency Medicine with a Joint Appointment in The Division of Infectious Diseases. He has been conducting research on varied infectious disease conditions focusing on advancing the approach to diagnosis and management in emergency settings since 1996. He areas of research have included studies on HIV/STIs, skin and soft tissue infections, sepsis, influenza, and COVID. Dr. Rothman has particular expertise in development, implementation and evaluation of rapid molecular diagnostics in emergency settings, working with an interdisciplinary team of experts in microbiology, infectious disease and public health. He had led a large number of federal and foundation funded studies, including a multicenter study assessing new diagnostics and therapeutic for sepsis, and an implementation evaluation to optimize the approach to therapeutic trials for infectious disease diagnostics and therapeutics in emergency departments. Currently he serves as Co-Director for the NIH/NIAID Center of Excellence for Influenza Surveillance and Research, and is a practicing emergency physician at The Johns Hopkins Hospital. He has also served as a consultant and advisor for a number of biotechnology companies, holds a series of patents in molecular diagnostics and has published over 200 peer reviewed publications. Dr. Rothman is also one of the founding members of the EMTIDE consortium, a network of academic emergency departments focused on research practice and policy on emerging and transmissible infectious diseases.
Dr. Wang is a professor in the Departments of Mechanical Engineering and Biomedical Engineering, where he has served on the faculty since 2002. Dr. Wang’s primary research focus is on the development of new technologies and methods for molecular analysis of diseases and biomedical research. Over the past decade, he has participated in the development of microfluidics, biomedical devices, single-molecule fluorescence spectroscopy, and multiplexing methods for the detection of infectious diseases and cancer. He has taken the leading roles in the development of several enabling technologies, such as quantum dot-fluorescence resonance energy transfer (QD-FRET) for highly sensitive genetic and epigenetic marker detection, digital high-resolution-melt-analysis (dHRMA) for broad-scale detection of pathogens, mobile nucleic acid amplification testing (mobiNAAT) for point-of-care testing, and dropFAST for droplet microfluidics enabled rapid antimicrobial susceptibility testing. Dr. Wang is currently leading several NIH and DoD funded projects for developing next-generation technology platforms of rapid testing and antimicrobial susceptibility detection for several infectious diseases including sepsis, unitary tract infection (UTI), and sexually transmitted infection (STI). He also leads other projects on developing highly sensitive epigenetic analysis platforms for screening and early detection for a variety of cancers, including lung, ovarian, colon, and esophagus. Dr. Wang is an inventor of 20 patents and has authored 130 research articles and 120 abstracts and oral presentations. He received the NSF CAREER Award in 2006, CSR Jorge Heller Award in 2007, ASGR Excellence in Research Award in 2007, the JALA Ten Award in 2011. He is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE), American Society of Mechanical Engineering (ASME), Institute of Electrical and Electronics Engineers (IEEE) and Royal Society of Chemistry (ROC). https://me.jhu.edu/thwang/